Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model

Binder, Natalie; Alwis, Natasha de; Beard, Sally; Kadife, Elif; Harper, Alesia; Kaitu’u-Lino, Tu’uhevaha J; Brownfoot, Fiona; Hannan, Natalie J.

doi:10.1016/j.placenta.2023.01.001

Cited by 1 publication

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ability of sulfasalazine to inhibit NFκB activity, and thus the levels of inflammatory factors, make it a strong candidate for treating preeclampsia. This drug reduces high blood pressure in pregnant mice developing preeclampsia caused by injection of a nitric oxide synthase antagonist, i.e., L-NAME [120]. This suggests that sulfasalazine may prevent the endothelial dysfunction least by upregulating the activity of eNOS and the production of vasodilatory factors such as nitric oxide [121].…”

Section: Anti-inflammatory Agents In the Treatment Of Preeclampsiamentioning

confidence: 99%

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Sakowicz

Bralewska

Rybak-Krzyszkowska

et al. 2023

IJMS

View full text Add to dashboard Cite

Preeclampsia (PE) is a pregnancy-specific disorder affecting 4–10% of all expectant women. It greatly increases the risk of maternal and foetal death. Although the main symptoms generally appear after week 20 of gestation, scientific studies indicate that the mechanism underpinning PE is initiated at the beginning of gestation. It is known that the pathomechanism of preeclampsia is strongly related to inflammation and oxidative stress, which influence placentation and provoke endothelial dysfunction in the mother. However, as of yet, no “key players” regulating all these processes have been discovered. This might be why current therapeutic strategies intended for prevention or treatment are not fully effective, and the only effective method to stop the disease is the premature induction of delivery, mostly by caesarean section. Therefore, there is a need for further research into new pharmacological strategies for the treatment and prevention of preeclampsia. This review presents new preventive methods and therapies for PE not yet recommended by obstetrical and gynaecological societies. As many of these therapies are in preclinical studies or under evaluation in clinical trials, this paper reports the molecular targets of the tested agents or methods.

show abstract

Section: Anti-inflammatory Agents In the Treatment Of Preeclampsiamentioning

confidence: 99%

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Sakowicz

Bralewska

Rybak-Krzyszkowska

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model

Cited by 1 publication

References 34 publications

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

New Ideas for the Prevention and Treatment of Preeclampsia and Their Molecular Inspirations

Contact Info

Product

Resources

About